세계의 생세포 이미징 시장(-2030년) : 제품(장치, 소모품, 소프트웨어 및 서비스), 용도(세포 생물학, 줄기 세포, 창약), 기술(타임랩스 현미경, FRET, FRAP, HCS), 최종사용자(제약 및 바이오테크놀러지, CRO)

The global live cell imaging market is projected to reach USD 4.75 billion in 2030 from USD 3.13 billion in 2025, growing at a CAGR of 8.68% during the forecast period. Ongoing advancements in imaging technologies, along with the rising cancer cases in the world, are factors supporting the growth of the market. Moreover, the availability of funds and grants for cellular biology research and the growing adoption of HCS techniques for drug discovery and research is increasing the demand for live cell imaging products and consumables, supporting the growth of the market. Key players are expanding their reach in emerging markets to grab new growth opportunities in the field of live cell imaging; however, this expansion is restricted due to the high cost of live cell imaging instruments, making these products inaccessible to small academic institutes and pharmaceutical companies.

The market for live cell imaging and analysis software is expected to witness the highest growth within the offerings segment during the forecast period.

The live cell imaging software market is expected to witness the highest growth during the forecast period within the offering segment. This high growth can be attributed to the growing demand for advanced data analysis, automation, and AI integration in cellular research. As imaging technologies become more advanced, researchers require powerful software tools to manage large volumes of complex image data, perform real-time analysis, and extract meaningful biological insights. The growing adoption of high-content screening, 3D imaging, and time-lapse microscopy further fuels the need for intelligent software capable of handling multi-dimensional datasets. In addition, the integration of machine learning and deep learning algorithms into imaging software is enabling faster and more accurate cell segmentation, tracking, and phenotyping, making these tools essential in drug discovery, cancer research, and regenerative medicine.

The pharmaceutical & biotechnology companies end user segment held the largest market share in the live cell imaging market, by end user, during the forecast period.

Pharmaceutical & biotechnology companies held the largest share of the live cell imaging market by end users in 2024. This large share can be attributed to the increasing demand for advanced imaging technologies in drug discovery, cell biology research, and personalized medicine. These companies heavily rely on live cell imaging to observe cellular behaviors, study disease mechanisms, and evaluate the effects of potential drug candidates in real time. The rise in the prevalence of chronic diseases and the growing need for precise therapies further fuel the adoption of live cell imaging technologies in these sectors. This trend is expected to continue during the forecast period of 2025-2030, driven by ongoing innovations in imaging technologies, the need for faster and more accurate drug development, and the growing importance of cellular research in therapeutic development.

Asia Pacific is expected to be the fastest-growing region in the live cell imaging market.

Asia Pacific is the fastest-growing region in the live cell imaging market, having the highest CAGR during the forecast period of 2025-2030. This growth is driven by increased investment in the healthcare and biotechnology sectors, along with the rising demand for advanced imaging technologies. China, Japan, and India are increasing their research and development activities, particularly in drug discovery and regenerative medicine, which require advanced imaging techniques. Additionally, government support for scientific research and the expanding focus on personalized medicine are key factors fueling this market growth in the region.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 44%, Tier 2- 32%, and Tier 3- 24%
• By Designation: (Managers)- 45%, (CXOs, Directors)- 30%, and (Executives)- 25%
• By Region: North America- 40%, Europe- 25%, Asia Pacific- 20%, Rest of the World- 15%

List of Companies Profiled in the Report:

• Danaher (US)
• Zeiss Group (Germany)
• Nikon Corporation (Japan)
• Evident (Japan)
• Revvity (US)
• Sartorius AG (Germany)
• Agilent Technologies, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• Nanoentek (Korea)
• Bruker (US)
• BD (US)
• Merck KGaA (Germany)
• Bio-Rad Laboratories, Inc. (US)
• Tecan Trading AG (Switzerland)
• Corning Incorporated (US)
• Sysmex Corporation (Japan)
• Blue-Ray Biotech Corp. (Taiwan)
• Curiosis Inc. (South Korea)
• CYTENA GmbH (Germany)
• Abberior Instruments America LLC (Germany)
• Phase Holographic Imaging PHI AB (Sweden)
• Aligned Genetics (South Korea)
• Cherry Biotech (France)
• Nanolive SA (Switzerland)
• CytoTronics (US)
• Etaluma, Inc. (US)
• Axion BioSystems, Inc (US)
• TissueGnostics GmbH (Austria)

Research Coverage:

This report provides a detailed picture of the global live cell imaging market. It aims to estimate the size and future growth potential of the market across different segments such as the offering, technology, application, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the live cell imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services, key strategies, partnerships, agreements, product and service launches, mergers and acquisitions, and recent developments associated with the live cell imaging market. Competitive analysis of upcoming startups in the live cell imaging market ecosystem is covered in this report.

Reasons to buy this report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall live cell imaging market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, Growing availability of funds for research, advancement in imaging technology), restraints (High cost of high-content screening systems), opportunities (increasing adoption of live cell imaging technologies in emerging markets, and application of HCS in personalized medicine), and challenges (maintaining cell viability and cellular environment in cell cultures, and image analysis and data management) influencing the growth of the live cell imaging market
• Product Development/Innovation: Detailed insight into newly launched products & services and technological assessment of the live cell imaging market
• Market Development: Comprehensive information about lucrative markets - the report analyses the live cell imaging market across varied regions.
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the live cell imaging market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and products and service offerings of leading players Danaher (US), Zeiss Group (Germany), Nikon Corporation (Japan), Evident (Japan), Revvity (US), Sartorius AG (Germany), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Nanoentek (Korea), Bruker (US), BD (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Corning Incorporated (US), Sysmex Corporation (Japan), Blue-Ray Biotech Corp. (Taiwan), Curiosis Inc. (South Korea), CYTENA GmbH (Germany), Abberior Instruments America LLC (Germany), Phase Holographic Imaging PHI AB (Sweden), Aligned Genetics (South Korea), Cherry Biotech (France), Nanolive SA (Switzerland), CytoTronics (US), Etaluma, Inc. (US), Axion BioSystems, Inc (US), and TissueGnostics GmbH (Austria) among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 INSIGHTS FROM PRIMARIES
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 GROWTH RATE FORECAST
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LIVE CELL IMAGING MARKET OVERVIEW
• 4.2 NORTH AMERICA: LIVE CELL IMAGING MARKET, BY OFFERING AND COUNTRY, 2024
• 4.3 LIVE CELL IMAGING MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)
• 4.4 LIVE CELL IMAGING MARKET, BY END USER, 2024
• 4.5 LIVE CELL IMAGING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing adoption of high-content screening techniques in drug discovery
    • 5.2.1.2 Rising incidence of cancer
    • 5.2.1.3 Growing availability of research funds
    • 5.2.1.4 Advancements in imaging technology
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Expensive high-content screening systems
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing adoption of live cell imaging technologies in emerging markets
    • 5.2.3.2 Growing applications of live cell imaging in personalized medicine
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Maintenance of cell viability and cellular environment in cell cultures
    • 5.2.4.2 Image analysis and data management
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
  • 5.4.2 AVERAGE SELLING PRICE, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
• 5.7 INVESTMENT AND FUNDING ACTIVITY
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Fluorescence microscopy
    • 5.8.1.2 Confocal microscopy
    • 5.8.1.3 Super-resolution microscopy
    • 5.8.1.4 Forster resonance energy transfer
    • 5.8.1.5 Fluorescence recovery after photobleaching
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Image analysis software
    • 5.8.2.2 Microfluidics
    • 5.8.2.3 Optogenetics
    • 5.8.2.4 Multiphoton microscopy
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Fixed cell imaging
• 5.9 PATENT ANALYSIS
• 5.10 TRADE DATA ANALYSIS
  • 5.10.1 IMPORT DATA FOR HS CODE 901120
  • 5.10.2 EXPORT DATA FOR HS CODE 901120
• 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.12 REGULATORY LANDSCAPE
  • 5.12.1 REGULATORY FRAMEWORK
    • 5.12.1.1 North America
      • 5.12.1.1.1 US
      • 5.12.1.1.2 Canada
    • 5.12.1.2 Europe
      • 5.12.1.2.1 UK
      • 5.12.1.2.2 European Union
    • 5.12.1.3 Asia Pacific
      • 5.12.1.3.1 Japan
      • 5.12.1.3.2 South Korea
      • 5.12.1.3.3 China
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT FROM NEW ENTRANTS
  • 5.13.2 THREAT FROM SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF SUPPLIERS
  • 5.13.4 BARGAINING POWER OF BUYERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 IMPACT OF AI/GENERATIVE AI ON LIVE CELL IMAGING MARKET
  • 5.15.1 INTRODUCTION
  • 5.15.2 KEY COMPANIES IMPLEMENTING AI
  • 5.15.3 AI USE CASES
  • 5.15.4 FUTURE OF AI IN LIVE CELL IMAGING ECOSYSTEM
• 5.16 IMPACT OF 2025 US TARIFF ON LIVE CELL IMAGING MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 KEY TARIFF RATES
  • 5.16.3 PRICE IMPACT ANALYSIS
  • 5.16.4 IMPACT ON COUNTRY/REGION
    • 5.16.4.1 US
    • 5.16.4.2 Europe
    • 5.16.4.3 Asia Pacific
  • 5.16.5 IMPACT ON END-USE INDUSTRIES
    • 5.16.5.1 Pharmaceutical & biotech companies
    • 5.16.5.2 Academic & research institutes
    • 5.16.5.3 Contract research organizations

6 LIVE CELL IMAGING MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 INSTRUMENTS
    • 6.2.1.1 Microscopes
      • 6.2.1.1.1 Ongoing technological advancements in microscopes to support growth
    • 6.2.1.2 Cell imaging systems
      • 6.2.1.2.1 Seamless integration and workflow efficiency of standalone systems to boost market
    • 6.2.1.3 Cell analyzers
      • 6.2.1.3.1 Accuracy and reproducibility of cell analyzers to encourage growth
    • 6.2.1.4 Accessories
      • 6.2.1.4.1 Increasing demand for live cell imaging in life science research to accelerate growth
  • 6.2.2 CONSUMABLES
    • 6.2.2.1 Reagents
      • 6.2.2.1.1 Widespread usage of reagents in life science research to foster growth
    • 6.2.2.2 Assay kits
      • 6.2.2.2.1 Higher customer convenience and time-saving solutions to amplify growth
    • 6.2.2.3 Media
      • 6.2.2.3.1 Increasing investments in cell-based research to intensify growth
    • 6.2.2.4 Other consumables
• 6.3 SOFTWARE
  • 6.3.1 INCREASING ADVANCEMENTS IN IMAGE ACQUISITION TO SUPPORT GROWTH
• 6.4 SERVICES
  • 6.4.1 GROWING DEMAND FOR OUTSOURCED EXPERTISE AND SPECIALIZED SERVICES TO FUEL MARKET

7 LIVE CELL IMAGING MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 TIME-LAPSE MICROSCOPY
  • 7.2.1 GROWING DEMAND FOR HIGH CONTENT AND HIGH THROUGHPUT ANALYSIS IN PRECLINICAL STUDIES TO DRIVE MARKET
• 7.3 FLUORESCENCE RESONANCE ENERGY TRANSFER
  • 7.3.1 ADVANCEMENTS IN FLUORESCENT MATERIALS AND PROBES TO BOOST MARKET
• 7.4 FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING
  • 7.4.1 INCREASING ADVANCEMENTS IN FLUORESCENT PROTEINS TO SPUR GROWTH
• 7.5 HIGH-CONTENT SCREENING
  • 7.5.1 GROWING FOCUS ON DRUG DISCOVERY AND TOXICITY SCREENING TO DRIVE MARKET
• 7.6 OTHER TECHNOLOGIES

8 LIVE CELL IMAGING MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 CELL BIOLOGY RESEARCH
  • 8.2.1 INCREASING FOCUS ON DISEASE RESEARCH TO SUPPORT GROWTH
• 8.3 DRUG DISCOVERY
  • 8.3.1 GROWING USE OF HIGH-CONTENT SCREENING CELL-BASED ASSAYS IN DRUG DISCOVERY STUDIES TO BOOST MARKET
• 8.4 STEM CELL RESEARCH
  • 8.4.1 INCREASING FOCUS ON REGENERATIVE MEDICINE TO EXPEDITE GROWTH
• 8.5 DEVELOPMENTAL BIOLOGY
  • 8.5.1 RISING INTEREST IN ORGANOGENESIS AND TISSUE MORPHOGENESIS TO PROMOTE GROWTH

9 LIVE CELL IMAGING MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 INCREASING R&D ACTIVITIES TO DEVELOP NEW DRUGS TO SUPPORT GROWTH
• 9.3 ACADEMIC & RESEARCH INSTITUTES
  • 9.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH PROGRAMS TO AID GROWTH
• 9.4 CONTRACT RESEARCH ORGANIZATIONS
  • 9.4.1 GROWING OUTSOURCING OF R&D ACTIVITIES BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET

10 LIVE CELL IMAGING MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC ANALYSIS FOR NORTH AMERICA
  • 10.2.2 US
    • 10.2.2.1 Presence of major players and increasing investments in life science research to sustain growth
  • 10.2.3 CANADA
    • 10.2.3.1 Government initiatives to promote research to aid growth
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC ANALYSIS FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Presence of large number of academic research institutes to boost market
  • 10.3.3 UK
    • 10.3.3.1 Investments by pharmaceutical sponsors for drug discovery services to foster market
  • 10.3.4 FRANCE
    • 10.3.4.1 Booming pharmaceutical manufacturing industry to drive market growth
  • 10.3.5 ITALY
    • 10.3.5.1 Strong research tradition, government funding, and collaborative research networks to fuel growth
  • 10.3.6 SPAIN
    • 10.3.6.1 Rising R&D expenditure to boost market
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC ANALYSIS FOR ASIA PACIFIC
  • 10.4.2 CHINA
    • 10.4.2.1 Low manufacturing cost and surge in research & development investments to spur growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Presence of large geriatric population and increasing research activities to bolster growth
  • 10.4.4 INDIA
    • 10.4.4.1 Growing pharmaceutical industry to propel market
  • 10.4.5 SOUTH KOREA
    • 10.4.5.1 Ongoing collaborations and research initiatives among market players to encourage growth
  • 10.4.6 AUSTRALIA
    • 10.4.6.1 Robust healthcare infrastructure to facilitate growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC ANALYSIS FOR LATIN AMERICA
  • 10.5.2 BRAZIL
    • 10.5.2.1 Growing focus on biotechnology and biomedical innovations to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Low manufacturing cost and large population to support growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MACROECONOMIC ANALYSIS FOR MIDDLE EAST
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Saudi Arabia
      • 10.6.2.1.1 Increasing life science research funding to aid growth
    • 10.6.2.2 UAE
      • 10.6.2.2.1 Presence of research institutes supporting live cell imaging studies to foster growth
    • 10.6.2.3 Rest of GCC Countries
  • 10.6.3 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 GOVERNMENT INITIATIVES TO CONTRIBUTE TO GROWTH
  • 10.7.2 MACROECONOMIC ANALYSIS FOR AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LIVE CELL IMAGING MARKET
• 11.3 REVENUE ANALYSIS, 2022-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
• 11.6 BRAND/PRODUCT COMPARISON
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
• 11.8 COMPANY FOOTPRINT, KEY PLAYERS, 2024
  • 11.8.1 COMPANY FOOTPRINT
  • 11.8.2 REGION FOOTPRINT
  • 11.8.3 OFFERING FOOTPRINT
  • 11.8.4 APPLICATION FOOTPRINT
• 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.9.1 PROGRESSIVE COMPANIES
  • 11.9.2 RESPONSIVE COMPANIES
  • 11.9.3 DYNAMIC COMPANIES
  • 11.9.4 STARTING BLOCKS
• 11.10 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
  • 11.10.1 DETAILED LIST OF KEY STARTUPS/SMES
  • 11.10.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
• 11.11 COMPETITIVE SCENARIO
  • 11.11.1 PRODUCT LAUNCHES AND UPGRADES
  • 11.11.2 DEALS
  • 11.11.3 EXPANSIONS

12 COMPANY PROFILE

• 12.1 KEY PLAYERS
  • 12.1.1 DANAHER
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches and upgrades
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 ZEISS GROUP
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches and upgrades
      • 12.1.2.3.2 Deals
      • 12.1.2.3.3 Expansions
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 THERMO FISHER SCIENTIFIC INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 REVVITY
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches and upgrades
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 SARTORIUS AG
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strength
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 NIKON CORPORATION
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Expansions
  • 12.1.7 EVIDENT
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Product launches and upgrades
  • 12.1.8 AGILENT TECHNOLOGIES, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product launches and upgrades
  • 12.1.9 NANOENTEK
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
  • 12.1.10 BRUKER
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Deals
  • 12.1.11 BD
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 MERCK KGAA
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 BIO-RAD LABORATORIES, INC.
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
  • 12.1.14 TECAN TRADING AG
    • 12.1.14.1 Business overview
  • 12.1.15 SYSMEX CORPORATION
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
  • 12.1.16 CORNING INCORPORATED
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
• 12.2 OTHER PLAYERS
  • 12.2.1 AXION BIOSYSTEMS, INC.
  • 12.2.2 BLUE-RAY BIOTECH CORP.
  • 12.2.3 CURIOSIS INC.
  • 12.2.4 CYTENA GMBH
  • 12.2.5 ABBERIOR GMBH
  • 12.2.6 PHASE HOLOGRAPHIC IMAGING PHI AB
  • 12.2.7 ALIGNED GENETICS INC.
  • 12.2.8 CHERRY BIOTECH
  • 12.2.9 NANOLIVE SA
  • 12.2.10 CYTOTRONICS
  • 12.2.11 ETALUMA, INC.
  • 12.2.12 TISSUEGNOSTICS GMBH

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS